You are here: Home: PCU Think Tank 1 | 2007: Audio Program Guide: PCU Think Tank 1 | 2007 Audio
 
  Go to Multimodality Therapy of Localized Disease
Go to Treatment of PSA-Only Disease
Go to Chemotherapy for Hormone-Refractory, Metastatic Disease
Go to Controversial Issues in Hormonal Therapy
 

To listen to individual tracks, click the track you wish to listen to.
To download tracks, right-click on the one you wish to download.

 
     
Section 1: Multimodality Therapy of Localized Disease
  Click here to download the entire segment  
Track 1 Duration of testosterone suppression and risk of death from prostate cancer for men treated with radiation therapy and six months of hormone therapy
Track 2 Clinical and investigational implications of data on the duration of testosterone suppression
Track 3 Recovery of testosterone following hormonal therapy
Track 4 Relevance of new data on the duration of testosterone suppression to intermittent hormonal therapy
Track 5 Evaluating the benefit of hormonal therapy for patients treated with radiation therapy
Track 6 Influence of duration of androgen suppression and cardiovascular risk

Track 7 Screening and identification of men at risk for cardiovascular morbidity from hormonal therapy
Track 8 Weighing the benefits of hormonal therapy against the risk of myocardial infarction
Track 9 Treatment approach for intermediate-risk prostate cancer
Track 10 Side effects and complications of radiation therapy versus prostatectomy
Track 11 Potential benefit of adjuvant hormonal therapy postprostatectomy
Track 12 Synergistic effect of radiation therapy and hormonal therapy
Track 13 Studies of neoadjuvant hormonal therapy before prostatectomy
Track 14 High-dose radiation therapy without hormonal therapy for patients with intermediate-risk prostate cancer

Track 15 Potential impact of diet and exercise on disease progression
Track 16 Duration of androgen suppression after radiation therapy with hormonal therapy
Track 17 Critical evaluation of the Early Prostate Cancer (EPC) trial of high-dose bicalutamide
Track 18 Influence of the long natural history of prostate cancer on clinical trial outcomes

Track 19 Potential confounding effect of prognostic factors on adjuvant trial results
Track 20 Issues in conducting adjuvant clinical trials in prostate cancer
     
     
Section 2: Treatment of PSA-Only Disease
  Click here to download the entire segment  
Track 1 Impact of hormonal therapy on patients with rapid PSA doubling time
Track 2 Robustness of PSA doubling time as a prognostic factor
Track 3 Impact of hormonal therapy on patients with moderate PSA doubling times
Track 4 Guidelines for the calculation of PSA doubling time
Track 5 Chemotherapy in patients with hormone-refractory, PSA-only relapse
Track 6 Impact of docetaxel on quality of life

Track 7 Side effects of docetaxel
Track 8 Use of growth factor support with docetaxel
Track 9 Impact of androgen deprivation versus docetaxel on quality of life
Track 10 Side effects associated with docetaxel in the setting of radiation therapy and hormonal therapy
Track 11 Reduced docetaxel-associated toxicity with DN-101, high-dose oral calcitriol
Track 12 Patient perspectives on docetaxel tolerability
Track 13 Value of delaying disease progression with chemotherapy

Track 14 Selection of patients with PSA-only disease for treatment with chemotherapy
Track 15 Monitoring PSA response to guide decision-making about continuing or discontinuing chemotherapy
     
Section 3: Chemotherapy for Hormone-Refractory, Metastatic Disease
  Click here to download the entire segment  
Track 1 Symptomatic and quality-of-life improvements with docetaxel in advanced prostate cancer
Track 2 Use of chemotherapy to delay the onset of symptomatic metastatic disease
Track 3 Factors influencing patients’ treatment decision-making
Track 4 Use of chemotherapy for elderly prostate cancer patients
Track 5 End-of-life and palliative care for patients with prostate cancer
Track 6 Impact of age and performance status on the likelihood of patients receiving chemotherapy

Track 7 Benefits of the oral platinum agent satraplatin in prostate cancer
Track 8 Satraplatin and trajectory of advanced hormone-refractory prostate cancer progressing on docetaxel
Track 9 Symptomatic improvement with satraplatin after progression on docetaxel
Track 10 Decision-making in the first-line metastatic setting
     
Section 4: Controversial Issues in Hormonal Therapy
  Click here to download the entire segment  
Track 1 SWOG-S9346: Intermittent versus continuous combined androgen deprivation for metastatic prostate cancer
Track 2 Use of risk stratification in selecting candidates for continuous versus intermittent hormonal therapy
Track 3 High-dose bicalutamide as a hormonal therapy alternative for patients with a slowly rising PSA
Track 4 Use of antiandrogen monotherapy
Track 5 Benefit from a 5-alpha reductase inhibitor in hormone-refractory prostate cancer
Track 6 Prognostic significance of PSA level after combined androgen blockade